Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating β-blocker, in patients with cirrhosis and portal hypertension-Reference-Cited by-同舟云学术

Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating β-blocker, in patients with cirrhosis and portal hypertension

Published:2002-03 Issue:3 Volume:16 Page:373-380
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

Tripathi D.,Therapondos G.,Lui H. F.,Stanley A. J.,Hayes P. C.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2036.2002.01190.x/fullpdf

Reference30 articles.

1. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study;Lebrec;Hepatology,1982

2. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients;Vorobioff;Hepatology,1987

3. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model;Kroeger;Hepatology,1985

4. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage [see comments];Groszmann;Gastroenterology,1990

5. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis;Feu;Lancet,1995

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacologic Treatment of Portal Hypertension;Clinics in Liver Disease;2024-08

2. Bleeding Complications of Portal Hypertension;Clinics in Liver Disease;2024-08

3. Pathophysiology and therapeutic options for cirrhotic portal hypertension;The Lancet Gastroenterology & Hepatology;2024-07

4. Comparison of 1‐day versus 3‐day intravenous terlipressin in cirrhosis patients with variceal bleeding: A pilot randomised controlled trial;Alimentary Pharmacology & Therapeutics;2024-01-07

5. Keep beta-blocking and carry on!;Clinical Liver Disease;2024-01